

Full Alliance Group, Inc.

201 Douglas Rd E, Oldsmar, Florida 34677

1 (800) 895 - 4415
fullalliance-group.com
info@fullalliance-group.com

Quarterly Report

For the period ending 3/31/2026 (the "Reporting Period")

Outstanding Shares

The number of shares outstanding of our Common Stock was:

135,788,511 as of March 31, 2026 *(Current Reporting Period Date or More Recent Date)*

135,788,511 as of December 31, 2025 *(Most Recent Completed Fiscal Year End)*

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: No:

Change in Control

Indicate by check mark whether a Change in Control⁵ of the company has occurred during this reporting period:

Yes: No:

1) Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer and names used by predecessor entities, along with the dates of the name changes.

⁵ "Change in Control" shall mean any events resulting in:

- (i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

Full Alliance Group, Inc. (“the Company”) formerly (fka Beverly Hills Group, Inc.) originally incorporated on March 2, 2000 as (fka The Motion Picture Hall of Fame, Inc.), symbol (OTCPK: MHFM). On June 5, 2014, the Company did a name change to Beverly Hills Group, Inc., and a symbol change to (OTCPK: BHGI), and on April 12, 2017 the Company did a name change to FULL ALLIANCE GROUP, INC., with a symbol change to (OTCPK: FAGI).

Full Alliance Group, Inc., 201 Douglas Rd E, Oldsmar, Florida 34677 United States

Current State and Date of Incorporation or Registration: Nevada March 2, 2000

Standing in this jurisdiction: (e.g. active, default, inactive): Active

Prior Incorporation Information for the issuer and any predecessors during the past five years:

Full Alliance Group, Inc. (fka Beverly Hills Group, Inc.) (“the Company”) was incorporated in the State of Nevada on March 2, 2000 as The Motion Picture Hall of Fame, Inc., on June 5, 2014 the Company did a name change to Beverly Hills Group, Inc., and on April 12, 2017 the Company did a name change to FULL ALLIANCE GROUP, INC. Full Alliance Group, Inc., is currently active in the State of Nevada.

Describe any trading suspension or halt orders issued by the SEC or FINRA concerning the issuer or its predecessors since inception:

NONE

List any company name change, stock split, dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On January 22, 2023, the Company entered into an Agreement and Plan of Merger with Bio Lab Naturals, Inc., a Florida corporation, manufacturing supplement products for white/private label customers and for its in-house brand Pure Factors, through its FDA-registered wholly owned subsidiary Pure Solutions, Inc., housed in a state-of-the-art 25,000 square foot facility in Tampa Florida. Pursuant to the Agreement, Full Alliance Group acquired all the outstanding shares of Bio Lab Naturals, Inc., in exchange for Twenty-five million (25,000,000) Class C Preferred Shares and Thirty-four million one hundred and thirty-six thousand nine hundred and ten (34,136,910) Class D Preferred shares, after the exchange, Full Alliance Group owns one hundred (100%) percent of Bio Lab Naturals common stock, and Bio Lab Naturals became a wholly-owned subsidiary of Full Alliance Group.

On January 22, 2023, a Special Meeting of the Shareholders of Full Alliance Group, Inc., voted and re-elected Ryan Gresham to the Board of Directors, Rudy Kiste was not re-elected.

On January 23, 2023, the Board of Directors held a meeting and voted in Ryan Gresham as President, CEO of the Company.

On January 27, 2023, a Special Meeting of the Shareholders of Full Alliance Group, Inc., voted and elected William Heneghan III and James Connell to the Board of Directors.

On January 27, 2023, the Board of Directors held a meeting and voted in William Heneghan III as COO of the Company. On April 24, 2023, the Company executed a purchase agreement to acquire 100% of the outstanding interest of DYNAMAXX International LTD in exchange for Ten million (11,000,000) Class E Preferred shares, Three Hundred Thousand Dollar (\$300,000.00) Promissory Note with an interest rate of five (5%) percent per annum with a Maturity date of April 24, 2026 and a three-year employment contract with Jay Archer appointing him Chief Revenue Officer. On April 20, 2023, the Board of Directors held a meeting and voted that as soon as practicable after the Closing of DYNAMAXX they would elect Jay Archer as the Chief Revenue Officer and to its Board of Directors.

On May 1, 2023, a Special Meeting of the Shareholders of Full Alliance Group, Inc., voted and elected Jay Archer to the Board of Directors.

On May 1, 2023, the Board of Directors held a meeting and voted in Jay Archer as the Chief Revenue Officer of the Company.

On March 29, 2024, four million (4,000,000) Class F Preferred Shares were authorized, par value \$0.001. Series F Preferred are being offered at \$0.50 cents for a total potential offering of \$2,000,000. (Management reserves the right to expand this offering.) Each Class F Preferred Share has antidilution consisting of the following: After a Thirty (30) for One (1) reverse split ("Split") of the common shares each share of Series F Preferred will automatically convert into 10X the number of common shares. (Example: if the common stock is trading at .01 Cents prior to split, with all things being equal it will be trading at .30 cents after split each \$1 invested in Series F Preferred will receive 20 shares of Common Shares after the Split.) In 2025, the Board authorized an additional two million (2,000,000) Class F Preferred Shares. As of September 30, 2025, the Company had issued \$2,192,500 and had an additional \$440,000 Subscribed, of Series F Preferred from 25 shareholders. On December 18, 2025 the Company authorized additional Class F Preferred Shares and Blank Check Preferred. The Company issued 880,000 class F Preferred shares for the \$440,000 previously subscribed.

On July 5, 2024, the Company entered two strategic joint ventures—FV Products International, LLC and WL Products International, LLC. The primary objective of FV Products is to develop and market proprietary health and beauty products directly to consumers through a robust eCommerce infrastructure, leveraging high-converting Video Sales Letters (VSLs) and targeted digital advertising. This direct-to-consumer (DTC) model allows the Company to retain higher margins while building long-term brand equity and customer loyalty. The eCommerce component includes subscription-based sales, influencer collaborations, and affiliate-driven campaigns, creating multiple channels for scalable growth. In parallel, WL Products International, LLC focuses on white-label manufacturing and private-label solutions, supplying premium supplements and cosmetic products to third-party brands. The Company maintains a controlling 51% ownership stake in both entities.

On December 19, 2024, the Company formed a joint venture with hypochlorous acid (HOCl) expert Michel Van Schaik to launch a manufacturing initiative under the name Aquaox Pure Solutions, LLC. This new venture, in which the Company also holds a 51% ownership stake, is dedicated to producing a line of eco-friendly, non-toxic, and highly effective HOCl-based products for use in cleaning, sanitization, and skincare. With rising consumer demand for natural, chemical-free alternatives, HOCl is gaining traction due to its broad-spectrum antimicrobial efficacy and its safety for use around humans and animals. The product line is designed for both industrial and personal applications, addressing needs across the medical, commercial, and consumer sectors. Both partners are to contribute \$50,000 in initial capital to fund startup operations and product development.

On December 8 and 18, 2025 the Company amended the authorized outstanding common and preferred to 850,000,000 and 150,000,000, respectfully. The Company also increased the authorized Class F Preferred stock from 4,000,000 to 6,000,000 all other designations of such Preferred remain the same. The Company also authorized and filed a new class of Preferred Stock Class QDP.

Address of the issuer's principal executive office:

201 Douglas Rd E, Oldsmar, Florida 34677

Address of the issuer's principal place of business:

Check if principal executive office and principal place of business are the same address:

201 Douglas Rd E, Oldsmar, Florida 34677

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: Yes: If Yes, provide additional details below:

2) Security Information

Transfer Agent

Name: Equiniti Trust Company, LLC (ISSUER DIRECT CORPORATION)
Phone: 1 919 - 744 - 2722
Email: Krista.Riley@equiniti.com
Address: One Glenwood Avenue Suite 1001, Raleigh, NC 27603

Publicly Quoted or Traded Securities:

The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.

Trading symbol:	FAGI
Exact title and class of securities outstanding:	Common Stock
CUSIP:	35968K 101
Par or stated value:	\$0.001
Total shares authorized:	850,000,000 as of date: March 31, 2026
Total shares outstanding:	135,788,511 as of date: March 31, 2026
Total number of shareholders of record:	330 as of date: March 31, 2026

Please provide the above-referenced information for all other publicly quoted or traded securities of the issuer.

NONE

Other classes of authorized or outstanding equity securities that do not have a trading symbol:

The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g., preferred shares that do not have a trading symbol). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.

Exact title and class of the security:	<u>Preferred Shares</u>
Par or stated value:	<u>\$0.001</u>
Total shares authorized:	<u>150,000,000</u> as of date: March 31, 2026
Total shares outstanding:	<u>100,401,910</u> as of date: March 31, 2026
Total number of shareholders of record:	<u>159</u> as of date: March 31, 2026

Please provide the above-referenced information for all other classes of authorized or outstanding equity securities.

NONE

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

Common Shares have 1 to 1 voting rights

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

Class "A" Preferred Shares have 1 to 10 voting rights and 1 to 2 conversion rights into Common Shares

Class "B" Preferred Shares have 0 voting and 0 conversion rights

Class "C" Preferred Shares have 1 to 10 voting rights and 1 to 11.32 conversion rights into Common Shares

Class "D" Preferred Shares have 1 to 1 voting rights and 1 to 1 conversion rights into Common Shares

Class "E" Preferred Shares have 1 to 1 voting rights and 1 to 10 conversion rights into Common Shares

Class "F" Preferred Shares have 1 to 1 voting rights and 1 to 10 conversion rights into Common Shares

Class "QDP" Preferred Shares – Certificate of Designation has not been determined

3. Describe any other material rights of common or preferred stockholders.

NONE

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

On January 23, 2023, the Shareholders approved and on February 24, 2023 the Company completed its Nevada State filings for the following changes;

Increased the Authorized Common Shares from 500,000,000 to 750,000,000

Increased the Authorized Preferred Shares from 50,000,000 to 100,000,000

Issued 25,000,000 Class "C" Preferred Shares

Issued 34,136,910 Class "D" Preferred Shares

Amended 25,000,000 Class "A" Preferred Shares from 1 to 7 to 1 to 2 conversion rights into Common Shares

Amended 25,000,000 Class "B" Preferred Shares to have 0 voting and 0 conversion rights

On May 1, 2023, the Shareholders approved and on May 12, 2023 the Company completed its Nevada State filings for the following changes;

Issued 11,000,000 Class "E" Preferred Shares

On March 29, 2024, the Shareholders approved and the Company completed its Nevada State filings for the following changes;

Authorized 4,000,000 Class "F" Preferred Shares, as of September 30, 2024.

On December 18, 2025, the Company completed its Nevada State filings for the following changes;

Increased Class “F” Preferred Shares to 6,000,000 Authorized;

Authorized the Issuance of 25,000,000 Class “QDP” Preferred Shares.

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer’s securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares for the two most recently completed fiscal years and any subsequent period.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes (If yes, you must complete the table below)

Shares Outstanding <u>Opening Balance:</u>			*Right-click the rows below and select “Insert” to add rows as needed.						
Date <u>January 1, 2024</u>									
Common: <u>111,410,711</u>									
Preferred: <u>95,136,910</u>									
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to. ***You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
March 29, 2024	new issuance	100,000	Preferred “F”	\$0.001	yes	Jim & Nancy Archer 6401 Steeple Chase Orange TX 77632	Investment	Restricted	144
March 29, 2024	new issuance	100,000	Preferred “F”	\$0.001	yes	Brian Davis 2807 Hidalgo St. Irving, TX 75062	Investment	Restricted	144
March 29, 2024	new issuance	40,000	Preferred “F”	\$0.001	yes	Josh Orensten 17781 Sage Ln Dallas, TX 75252	Investment	Restricted	144
March 29, 2024	new issuance	200,000	Preferred “F”	\$0.001	yes	Robert J. Shmyr 201 Douglas Rd E Oldsmar, FL 34677	Investment	Restricted	144
March 29, 2024	new issuance	200,000	Preferred “F”	\$0.001	yes	Marcell Enns 201 Douglas Rd E Oldsmar, FL 34677	Investment	Restricted	144
March 29, 2024	new issuance	560,000	Preferred “F”	\$0.001	yes	Darius Hawkinks & Dustie Patty 2163 Township Line Rd. Poplar Bluff, MO 63901	Investment	Restricted	144
March 29, 2024	new issuance	200,000	Preferred “F”	\$0.001	yes	Jeff Jacomine PO Box 1417 Hildebran, NC 28637	Investment	Restricted	144

March 29, 2024	new issuance	30,000	Preferred "F"	\$0.001	yes	Weston & Samantha Brainerd 310 Driftwood Lane Argyle, TX 76226	Investment	Restricted	144
March 29, 2024	new issuance	120,000	Preferred "F"	\$0.001	yes	Troy Sambrano 2020 Lake Landing dr. League City, TX 77573	Investment	Restricted	144
March 29, 2024	new issuance	120,000	Preferred "F"	\$0.001	yes	Charles & Laura Trentham 2237 Oak Hill Dr. Deland, FL 32720	Investment	Restricted	144
March 29, 2024	new issuance	1,000,000	Preferred "F"	\$0.001	yes	Paul Wagoneer 7908 Laporte Place Dallas, TX 75231	Investment	Restricted	144
April 9, 2024	new issuance	100,000	Preferred "F"	\$0.001	yes	Robert J. Shmyr 201 Douglas Rd E Oldsmar, FL 34677	Investment	Restricted	144
April 11, 2024	new issuance	40,000	Preferred "F"	\$0.001	yes	Eva Hood 221 Gatewood Circle E, Burleson, TX 76028	Investment	Restricted	144
April 11, 2024	new issuance	80,000	Preferred "F"	\$0.001	yes	Charles & Laura Trentham 2237 Oak Hill Dr. Deland, FL 32720	Investment	Restricted	144
April 12, 2024	new issuance	100,000	Preferred "F"	\$0.001	yes	Marcell Enns 201 Douglas Rd E Oldsmar, FL 34677	Investment	Restricted	144
June 4, 2024	new issuance	50,000	Preferred "F"	\$0.001	yes	Robert J. Shmyr 201 Douglas Rd E Oldsmar, FL 34677	Investment	Restricted	144
July 8, 2024	Assignment	300,000	Preferred "A"	\$0.001	yes	SUNG HO LEE 32 ROFF AVE PALISADES PARK, NJ 07650	Investment	Restricted	144
July 8, 2024	Assignment	500,000	Preferred "A"	\$0.001	yes	Paul Brian Volpp 539 Verbena Ct., Encinitas, CA 92024	Investment	Restricted	144
July 8, 2024	Assignment	1,000,000	Preferred "A"	\$0.001	yes	Ryan Gresham 20906 Pricewood Manor Ct., Cypress TX 77433	Investment	Restricted	144
July 29, 2024	New issuance	40,000	Preferred "F"	\$0.001	yes	Lane Holdings, LLC Attn: Will Lane 105A Page Rd Nashville, TN 37205	Investment	Restricted	144
August 8, 2024	New issuance	400,000	Preferred "F"	\$0.001	yes	Marcell Enns 201 Douglas Rd E Oldsmar, FL 34677	Investment	Restricted	144
September 4, 2024	New issuance	20,000	Preferred "F"	\$0.001	yes	Lee R Dreyer PO Box 1856 Eureka, MT 59917	Consulting	Restricted	144
September 23, 2024	New issuance	270,000	Preferred "F"	\$0.001	yes	Tim Francis Keeffe 4765 N Tomoka Drive, De Leon Springs, FL 32130	Investment	Restricted	144
December 5, 2024	New issuance	20,000	Preferred "F"	\$0.001	yes	Kathryn and Mark Engstrom 5644 Sun Up Road Land O Lakes, FL 34638	Investment	Restricted	144
December 18, 2024	New issuance	7,000,000	Common	\$0.0025	yes	Sabahat Ullah 33 Galingale View Newcastle, UK ST5 2GQ	Note conversion	Unrestricted	144
December 18, 2024	New issuance	5,538,900	Common	\$0.0025	yes	Valerian Capital, LLC, 131 Auburn Drive Lake Worth Beach Florida 33460 (Daniel Frid)	Note conversion	Unrestricted	144
March 28, 2025	New issuance	60,000	Preferred "F"	\$0.001	yes	Kathryn and Mark Engstrom 5644 Sun Up Road Land O Lakes, FL 34638	Investment	Restricted	144

April 24 2025	New issuance	5,538,900	Common	\$0.0025	yes	Snazzy Buys, Inc. Marilyn Phillips 3435 Williston Loop, Land O' Lakes, FL 34639	Note conversion	Unrestricted	144
June 30 2025	New issuance	25,000	Preferred "F"	\$0.001	yes	Cristy Roman PO BOX 17437 Fernandina Beach, FL 32035	Investment	Restricted	144
June 30 2025	New issuance	40,000	Preferred "F"	\$0.001	yes	Brian & Mim Davis 4702 O'Connor Court Irving, TX 75062	Investment	Restricted	144
June 30 2025	New issuance	20,000	Preferred "F"	\$0.001	yes	Howard Cracower 12 Gordon Crescent Court Meaford, ON N4L OA9 Canada	Investment	Restricted	144
June 30 2025	New issuance	50,000	Preferred "F"	\$0.001	yes	Michel Van Schlaik 7355 Hamlin Blvd Loxahatchee, Florida 33470	Investment	Restricted	144
June 30 2025	New issuance	200,000	Preferred "F"	\$0.001	yes	Heather Joyner 113 23rd Ave NE Hickory, NC 28601	Investment	Restricted	144
June 30 2025	New issuance	100,000	Preferred "F"	\$0.001	yes	Valerio Fortunato Via marcandreola 16H Ciampino, 00043 RM Italy	Investment	Restricted	144
June 30 2025	New issuance	100,000	Preferred "F"	\$0.001	yes	Fahria Ibrahim Via marcandreola 16H Ciampino, 00043 RM Italy	Investment	Restricted	144
Nov 7, 2025	New issuance	6,300,000	Common	\$0.001	Yes	New Orleans Private Wealth Management Andy Galy 709 Williams BLVD Kenner LA 70062	Note Conversion	Unrestricted	144
December 18.2025	New issuance	180,000	Preferred "F"	\$0.001	yes	Edwin McGusty 200 4 th Street South Unit 226 St Petersburg, FL 33701	Investment	Restricted	144
December 18.2025	New issuance	200,000	Preferred "F"	\$0.001	yes	Heather Joyner 113 23rd Ave NE Hickory, NC 28601	Investment	Restricted	144
December 18.2025	new issuance	200,000	Preferred "F"	\$0.001	yes	Troy Sambrano 2020 Lake Landing dr. League City, TX 77573	Investment	Restricted	144
December 18.2025	new issuance	100,000	Preferred "F"	\$0.001	yes	James Awtrej 7207 Sangalla Drive Windermere, FL 34786	Investment	Restricted	144
December 18.2025	new issuance	200,000	Preferred "F"	\$0.001	yes	Paul Wagoneer 7908 Laporte Place Dallas, TX 75231	Investment	Restricted	144
Shares Outstanding on Date of This Report:									
<u>Ending Balance:</u>									
Date <u>March 31, 2026</u>									
Common: <u>135,788,511</u>									
Preferred: <u>100,401,910</u>									

Example: A company with a fiscal year end of December 31st 2024, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2023 through December 31, 2024 pursuant to the tabular format above.

Any additional material details, including footnotes to the table are below:

During the 2023 Q2 period, 1,863,525 Restricted Preferred Shares were transferred from Dale Phillips to Marilyn R Phillips.
During the 2023 Q4 period, 2,496,795 Restricted Preferred Shares were transferred from First Count, LLC to Hugh Buck.
During the 2023 Q4 period, 2,496,795 Restricted Preferred Shares were transferred from Six Hearts, LLC to Marilyn R Phillips.
On July 8, 2024 300,000 Restricted Preferred Shares were transferred from Palm Desert Management Inc. to Sung Ho Lee.
On July 8, 2024 500,000 Restricted Preferred Shares were transferred from Palm Desert Management Inc. to Paul Brian Volpp.
On July 8, 2024 1,000,000 Restricted Preferred Shares were transferred from Palm Desert Management Inc. to Ryan Gresham.

On July 8, 2024, due to the above three assignments Palm Desert Managements Preferred Shares were reduce from 25,000,000 to 23,200,000 Preferred Shares.

See Notes to the Financial Statements for further details

B. Convertible Debt

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ⁶	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)
April 1, 2014	\$335,850.00	\$128,293.96	Mar 31, 2026	conversion price of two and one half tenths of a Cent (\$0.0025) per share	100,425,320	51,317,584	New Orleans Private Wealth Management LLC Andy Galy 709 Williams Blvd Kenner, LA 70062	Convertible Note
Mar 31, 2020	\$200,000.00	\$256,958.72	Mar 31, 2025	conversion price of two and one half tenths of a Cent (\$0.0025) per share	5,538,900	102,783,488	Snazzy Buys, Inc. Marilyn Phillips 3435 Williston Loop, Land O' Lakes, FL 34639	Convertible Note
Sep 30, 2020	\$9,345.00	\$12,201.71	Mar 31, 2025	conversion price of two and one half tenths of a Cent (\$0.0025) per share	0	4,880,584	Palm Desert Management, Inc. Rodolfo Kiste 4 Manitoba Way Marlboro, NJ 07746	Convertible Note
Total Outstanding Balance:		\$397,592.39		Total Shares:	105,964,220	158,981,756		

Any additional material details, including footnotes to the table are below:

On July 1, 2019, a portion of the March 31, 2017 Note, originally in the amount of \$64,623.62, was assigned \$25,000.00 to Paul Brian Volpp and \$25,000.00 to Ryan Gresham.

On Aug 20, 2019, a portion of the September 30, 2017 Note, originally in the amount of \$50,862.74, was assigned \$25,000.00 to Sung Ho Lee.

On March 31, 2020, Steven Joel Chrisco was assigned a portion, in the amount of \$200,000.00, of the original September 30, 2017 Palm Desert Management Note in the amount of \$241,239.60.

On March 31, 2020, the Company negotiated a deal with a related party Note holder, who was holding Notes totaling \$437,585.55 principle and \$188,926.51 interest, to convert the total principle and interest into the existing Preferred A shares already held by the related party note holder, by not increasing the amount of Preferred A shares issued, but by increasing only it's convertibility from Preferred A shares to Common Shares, with an increase from 1 to 5 shares to 1 to 7 shares.

On March 25, 2021, the unrelated party Note Holder assigned and transferred a \$76,000.00 portion of the Convertible Note, after the transfer having an outstanding balance of principle plus interest of \$157,315.93 as of March 25, 2021, to another unrelated entity ("unrelated Holder" Pinnacle Consulting Services, Inc.), and permits the unrelated Holder to convert principal, into shares of common stock at a conversion price of \$0.0025 per share.

On January 22, 2023, under the terms of the FAGI – Bio Labs Agreement, the unrelated party Note Holder, Pinnacle Consulting Services, Inc., reduced and cancel 50% of the outstanding balance of its Convertible Note, thereby reducing the outstanding balance to \$38,683.52.

On January 23, 2023, Steven Joel Chrisco assigned his Note, in the amount of \$200,000.00 principal and \$33,041.10 accrued interest to GTMALLDAY LLC.

On June 7, 2023, FAGI and Pinnacle Consulting Services, Inc. entered into a Settlement Agreement which extinguished all outstanding balance of its Convertible Note of \$16,332.49.

On November 27, 2023, GTMALLDAY LLC., assigned their Note, in the amount of \$200,000.00 principal and \$42,016.44 accrued interest to Snazzy Buys, Inc.

⁶ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

On July 8, 2024, 300,000 Restricted Preferred Shares were transferred from Palm Desert Management Inc. to Sung Ho Lee in exchange for Sung Ho Lee to extinguish his outstanding balance of \$25,000.00 Convertible note resulting in a balance of \$0 at September 30, 2024.

On July 8, 2024, 500,000 Restricted Preferred Shares were transferred from Palm Desert Management Inc. to Paul Brian Volpp. in exchange for Paul Brian Volpp to extinguish his outstanding balance of \$25,000.00 Convertible note resulting in a balance of \$0 at September 30, 2024.

On July 8, 2024, 1,000,000 Restricted Preferred Shares were transferred from Palm Desert Management Inc. to Ryan Gresham in exchange for Ryan Gresham to extinguish his outstanding balance of \$28,500.00 Convertible note resulting in a balance of \$0 at September 30, 2024.

On October 8, 2024, Snazzy Buys, Inc. converted \$13,847.25 of its Note for 5,538,900 common shares of Full Alliance Group, Inc. (FAGI), reducing the Outstanding Note balance plus interest to \$243,035.52, as of December 31, 2024, the shares were issued on April 24, 2025.

On November 7, 2024, Global Force Trading Limited assigned and converted \$17,500.00 of its Note for 7,000,000 common shares of Full Alliance Group, Inc. (FAGI) to Sabahat Ullah.

On November 15, 2024, Global Force Trading Limited assigned and converted \$13,847.25 of its Note for 5,538,900 common shares of Full Alliance Group, Inc. (FAGI), to Valerian Capital, LLC, Daniel Frid.

On July 1, 2025, Global Force Trading Limited assigned their Note, in the amount of \$35,179.12 principal and \$107,655.74 accrued interest to New Orleans Private Wealth Management, LLC.

On November 7, 2025, New Orleans Private Wealth Management, LLC. converted \$15,750.00 of its Note for 6,300,000 common shares of Full Alliance Group, Inc. (FAGI), reducing the Outstanding Note balance plus interest to \$128,006.51, as of December 31, 2025.

See Notes to the Financial Statements for further details

4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. Ensure that these descriptions are updated on the Company's Profile on www.OTCMarkets.com.

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

EBOO provides treatments and alternative health protocols, tailored to address specific health concerns. These protocols may provide relief and support for the following health conditions: cardiovascular disease, anxiety and depression, auto immune and inflammatory conditions, mold related issues, nutritional deficiencies, general health and wellness, Lyme disease, gut health and digestive issues, cancer support, hormonal imbalances, chronic pain and have been shown to help many more.

Pure Solutions is a registered and certified vitamin and supplement manufacturer by the United States Food & Drug Administration, The State of Florida Health Department, and The Department of Agriculture. Producing a wide range of quality vitamin and supplement product formats, including; capsules, tinctures, stick packs, powders and liquids. The company specializes in custom product development and FDA-compliant contract manufacturing, with a passion for cutting-edge formulations and innovative product selection. Pure Solutions is actively growing its customer base through joint ventures, partnerships, exclusive manufacturing agreements, by adding diversity to its in-house product line.

DYNAMAXX International LTD ("DYNAMAXX") is a holding company operating in the direct selling channel with its main operations in the United States and Canada.

DYNAMAXX offers a number of health and wellness products under the DYNAMAXX/GEMINI Brands including its best-selling products LIGHTS ON and LIGHTS OFF daily drink products. LIGHTS ON is a daytime powdered drink that contains a synergistic blend of Glucosamine HCL (known to help joint mobility), extraordinary botanicals, and vitamins with multiple benefits. LIGHTS ON, improves focus, concentration, clarity, and performance with smooth long-lasting energy. LIGHTS OFF is a nighttime powdered drink that supports deep relaxation, followed by restful, restorative sleep without waking up groggy or sluggish.

During the quarter ended September 30, 2023, DYNAMAXX and GEMINI Brands stopped operating as independent brands and combined each of their products under the DYNAMAXX brand.

In addition to having a world class supplement product line, DYNAMAXX has a cost-effective way for individuals to participate in the ever-growing GIG economy by offering an aggressive compensation program to those that refer customers who purchase products or customers who want to start their own business. DYNAMAXX offers training and support to their distributors, and has a strong focus on helping people achieve financial freedom through their business opportunities.

Subsequent to the quarter ended September 30, 2023, DYNAMAXX launched the first ever cash pay medical referral network through its independent reps (“Members”); allowing its Members to refer friends, family, other Members and customers to doctors who participate in the Dynamaxx Health Network. Initially, Dynamaxx Health Inc. is referring patients for EBOO procedure to Doctors’ in the network.

The two strategic joint ventures the company entered into—FV Products International, LLC and WL Products International, LLC. The primary objective of FV Products is to develop and market proprietary health and beauty products directly to consumers through a robust eCommerce infrastructure, leveraging high-converting Video Sales Letters (VSLs) and targeted digital advertising. This direct-to-consumer (DTC) model allows the Company to retain higher margins while building long-term brand equity and customer loyalty. The eCommerce component includes subscription-based sales, influencer collaborations, and affiliate-driven campaigns, creating multiple channels for scalable growth. To further support these efforts, the Company has brought on a seasoned team of marketing experts within FV Products to oversee campaign strategy, media buying, creative production, and performance tracking. In addition, a dedicated digital development team has been assembled to build out custom websites, user-friendly funnels, and fully optimized checkout experiences that align with each product’s unique positioning. This infrastructure is designed to support multiple upcoming product launches and increase average order value and customer lifetime value across the portfolio. In parallel, WL Products International, LLC focuses on white-label manufacturing and private-label solutions, supplying premium supplements and cosmetic products to third-party brands. In November, the Company successfully launched an additional white-label product through WL Products and has since expanded its marketing efforts, including outbound B2B outreach, co-branded packaging options, and sales enablement tools, to grow visibility, open new accounts, and drive revenue across both consumer and white-label divisions.

On September 17, 2024, the Company expanded by acquiring a second location in Westchase. This facility, formerly an established spa, is currently being converted to offer the full suite of MAXX Health’s cutting-edge anti-aging services, including EBOO (Extracorporeal Blood Oxygenation and Ozonation) therapy. The clinic comes with an existing customer base and a strong local reputation, providing a solid foundation for rapid growth. By integrating MAXX Health’s advanced treatments and wellness protocols, the Company expects to significantly enhance the value and experience offered to current clients. This strategic acquisition allows for immediate brand exposure in a new market and minimizes the ramp-up period typically required for a new clinic.

This Aquaox Pure Solutions, LLC venture focuses on producing a line of eco-friendly, non-toxic, and highly effective HOCl-based products for cleaning, sanitization, and skincare. As demand grows for natural, chemical-free solutions, HOCl continues to gain momentum due to its broad-spectrum antimicrobial properties and its proven safety around both humans and animals. The product line is tailored to serve a wide range of industries, including medical, commercial, and consumer markets.

To meet anticipated demand for our Nanobubble HOCl and Nanobubble HOCl gel products, we have dedicated a specialized space in our manufacturing facility to house six machines, with additional capacity available to support future growth.

On July 15, 2025, the Company formed Qubitera Holdings, Inc. a technology division focused on developing a quantum-secure digital infrastructure for healthcare, payments, personal security, and future capital-markets applications. Qubitera’s initiatives include the Quant Blockchain, a post-quantum-resistant ledger designed for medical, merchant, and fintech uses. The Quantum Personal Security Vault for identity and document protection; a

decentralized, patient-directed Electronic Health Record (EHR) platform; and ongoing evaluation of compliant tokenized equity structures. These initiatives are intended to establish the foundational technology layers for future products, services, and commercialization opportunities

On August 5, 2025, the Company formed Qubee Hive Holdings, Inc. a fintech division focused on Web 3 initiatives including YAHBEE its cross-chain wallet for integrated crypto and fiat payments; and YAHIVE its multi-tier affiliate rewards network and shopping platform.

The company's current websites:

<https://fullalliance-group.com/>
<https://puresolutionsusa.com/>
<https://purefactorsusa.com/>
<https://www.DynaMaxx.com>
<https://www.DynaMAXXHealth.com>
<https://maxxhealthclinics.com/>
<https://www.MaxxProviders.com>
<https://www.BuyPRiVIVE.com>
<https://www.DynaMAXXDirect.com>
<https://www.pureaquaox.com>
<https://www.aquaox.net>
<https://www.yahbee.com>

B. List any subsidiaries, parent company, or affiliated companies.

Full Alliance Group, Inc.,

Subsidiary companies:

Bio Lab Naturals, Inc.

Pure Solutions, Inc.

Trainers Elite Network, Inc.

DYNAMAXX International LTD.

Dynamaxx Health, Inc.

Dynamaxx Clinics SPV I, LLC

MAXX Health Clinic FL I LLC

FV Products International LLC

WL Products International LLC

Aquaox Pure Solutions, LLC

Qubitera Holdings, Inc.

Qubee Hive Holdings, Inc.

BEV Capital, LLC

C. Describe the issuers' principal products or services.

Complementary and alternative medicine (**CAM**) is the term for medical products and practices that are not part of standard **medical care**.

EBOO treatments provide alternative health protocols, tailored to address specific health concerns. These protocols may provide relief and support for the following health conditions: cardiovascular disease, anxiety and depression, auto immune and inflammatory conditions, mold related issues, nutritional deficiencies, general health and wellness, Lyme disease, gut health and digestive issues, cancer support, hormonal imbalances, chronic pain and have been shown to help many more.

EBOO, is a modern high volume blood gas exchange unit for the treatment of blood with medical ozone, the unit allows extracorporeal blood and oxygenation and ozone exposure and blood filtration via the filter in a unique way by using the integrated diffusing membranes within the filter fibers to trap lipids and proteins which are in excess in the venous blood supply.

Bio Lab Naturals, Inc. through its FDA-registered wholly-owned subsidiary Pure Solutions, Inc. manufactures supplement products for white/private label customers and its in-house brand Pure Factors. Pure Solutions is a developer, manufacturer, wholesale distributor of dietary supplements and cosmeceuticals, having 22 years' experience in the industry. Pure Solutions recently relocated its manufacturing facility to Oldsmar Florida; and is ready to expand its operations as it is seeking its cGMP certification.

DYNAMAXX International Ltd., is a direct selling entity that has a vast array of health and wellness products that it sells to the consumers through its Members.

Dynamaxx Health, Inc, is involved in providing health care services through its Maxx providers network and is in the process of opening clinics initially in Florida which provide anti-aging and rejuvenation cash based medical services becoming the first ever cash based direct selling medical referral company; essentially allowing each independent business representative the opportunity to participate in the ever-growing anti-aging medical spa industry.

FV Products International, LLC is a direct-to-consumer health and beauty company focused on developing and marketing proprietary supplements and cosmetic products through eCommerce platforms. The brand utilizes high-converting Video Sales Letters (VSLs), digital advertising, and subscription models to drive growth and customer acquisition. WL Products International, LLC complements this strategy by offering white-label and private-label solutions for other brands in the supplements and cosmetics space.

Aquaox Pure Solutions, LLC is a joint venture specializing in the development and manufacturing of hypochlorous acid-based products for cleaning, sanitizing, and skincare applications. The company focuses on delivering safe, non-toxic, and eco-friendly solutions to meet growing consumer demand for natural alternatives across personal care, medical, and commercial markets.

Qubee Hive Holdings Inc. is focused on developing and commercializing a connected Web3 financial and commerce ecosystem through the YAHBEE Wallet, the YAHIVE Affiliate Network, and the YAHBEE shopping platform. The Company's strategy is to combine digital wallet functionality, affiliate-based rewards, merchant participation, and shopping activity into one integrated platform designed to support payments, user engagement, referral compensation, and digital commerce. During the period, the Company continued to invest in infrastructure, compliance, technology development, strategic partnerships, and platform readiness, with the objective of building a scalable revenue model driven by wallet activity, affiliate network participation, merchant transactions, platform fees, and future digital asset-enabled services. Management believes these initiatives position Qubee Hive Holdings Inc. to participate in the growing convergence of fintech, e-commerce, affiliate marketing, and blockchain-enabled consumer applications.

5) Issuer's Facilities

The goal of this section is to provide investors with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer. Describe the location of office space, data centers, principal plants, and other property of the issuer and describe the condition of the properties.

Specify if the assets, properties, or facilities are owned or leased and the terms of their leases. If the issuer does not have complete ownership or control of the property, describe the limitations on the ownership.

The Company's subsidiary Bio Lab Naturals, Inc., through its subsidiaries Pure Solutions, Inc., and Aquaiox Pure Solutions LLC located in Oldsmar, Florida. at 14150 McCormick Drive, Tampa, Florida 33626. The lease was entered in April 2026 for a term of three years, is \$6,866 per month and is in a FDA-compliant, temperature-controlled facility which warehouses our manufacturing and fulfillment center, allowing the Company to do custom product development and FDA-compliant contract manufacturing.

6) All Officers, Directors, and 5% Beneficial Owners of the Company

Using the table below, please provide information, as of the period end date of this report, regarding all officers and directors of the company, or any person that performs a similar function, regardless of the number of shares they own.

In addition, list all individuals or entities controlling 5% or more of any class of the issuer's securities.

If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity. Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide investors with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial owners.

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, ≥ 5% beneficial owner)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
William Heneghan III	Officer/Director	201 Douglas Rd E Oldsmar, FL 34677	3,553,023	Preferred	3.49%
James Connell	Director	184 Sandy Hook Road Sarasota, FL 34242	2,429,161	Common	1.79%
Palm Desert Management, Inc. Rodolfo Kiste	Owner of more than 5%	44489 Town Center Way D112 Palm Desert, CA 92260	1,331,634	Common	0.98%
Palm Desert Management, Inc. Rodolfo Kiste	Owner of more than 5%	44489 Town Center Way D112 Palm Desert, CA 92260	23,200,000	Preferred	22.85%
Rodolfo Kiste	Owner of more than 5%	4 Manitoba Way Marlboro, NJ 07746	2,000,000	Common	1.47%
Ryan Gresham	Officer/Director	20906 Pricewood Manor Ct., Cypress TX 77433	556,633	Common	0.40%
Ryan Gresham	Officer/Director	20906 Pricewood Manor Ct., Cypress TX 77433	1,000,000	Preferred	0.98%
Carlo Magno & Lynn Riedl	Owner of more than 5%	36388 N 110TH WAY SCOTTSDALE, AZ 85262	10,000,000	Common	7.36%
Joel Casoria	Owner of more than 5%	2312 Walker Glen Buford, Georgia 30519	7,000,000	Common	5.15%
James Powers Jr	Owner of more than 5%	201 Douglas Rd E Oldsmar, FL 34677	5,317,616	Preferred	5.23%
Jay Archer	Officer/Director	6288 Blakeford Dr. Windermere FL 34786	11,000,000	Preferred	10.83%

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, log in to www.OTCIQ.com to update your company profile.

7) Legal/Disciplinary History

A. Identify and provide a brief explanation as to whether any of the persons or entities listed above in Section 6 have, in the past 10 years:

1. Been the subject of an indictment or conviction in a criminal proceeding or plea agreement or named as a defendant in a pending criminal proceeding (excluding minor traffic violations);

NONE

2. Been the subject of the entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, financial- or investment-related, insurance or banking activities;

NONE

3. Been the subject of a finding, disciplinary order or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, a state securities regulator of a violation of federal or state securities or commodities law, or a foreign regulatory body or court, which finding or judgment has not been reversed, suspended, or vacated;

NONE

4. Named as a defendant or a respondent in a regulatory complaint or proceeding that could result in a "yes" answer to part 3 above; or

NONE

5. Been the subject of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

NONE

6. Been the subject of a U.S Postal Service false representation order, or a temporary restraining order, or preliminary injunction with respect to conduct alleged to have violated the false representation statute that applies to U.S mail.

NONE

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party to or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NONE

8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Confirm that the information in this table matches your public company profile on www.OTCMarkets.com. If any updates are needed to your public company profile, update your company profile.

Securities Counsel

Name: Kenneth C. Grace, Esq., Grace Law PLLC
Address 1: 3903 Northdale Blvd.; Suite 100E
Address 2: Tampa, FL 33624
Phone: 1.844.536.4722
Email: Ken@GraceLawFlorida.com

Name: Michael Bennett
Address 1: 3582 W Grassland Dr,
Address 2: Lehi, UT 84043
Phone: 503 683 3180
Email: mbennett@juraalantes.com

Accountant or Auditor

Names: Natalie Collins
Firm: Total CFO, LLC
Address 1: 5132 Land O' Lakes Boulevard, STE 107
Address 2: Land O' Lakes, Florida 34639
Phone: (813) 909-9191
Email: CFO@TotalCFO.com, NCollins@TotalCFO.com

Investor Relations

Firm: Erelations Group, Gabe P. Rodriguez
Address 1: 1036 E Lincoln Ave.
Address 2: Escondido, CA 92026
Phone: (623) 261-9046
Email: Erelationsgroup@gmail.com

All other means of Investor Communication:

X (Twitter):
Discord:
LinkedIn: <https://www.linkedin.com/company/full-alliance-group-inc-otc-fagi/>
Facebook:
[Other]

Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

N/A

9) Disclosure & Financial Information

A. This Disclosure Statement was prepared by (name of individual):

Name: **William Heneghan III**
Title: **Chief Operating Officer and Principal Financial Officer**
Relationship to Issuer: **COO and PFO**

B. The following financial statements were prepared in accordance with:

- IFRS
 U.S. GAAP

C. The following financial statements were prepared by (name of individual):

Name: **Natalie Collins**
Title: **CFO Services Provider**
Relationship to Issuer: **CFO Services Provider**

Describe the qualifications of the person or persons who prepared the financial statements:⁷ **Bachelor of Science in Accounting from St. Leo University, founder and owner of Total CFO, LLC.**

Provide the following qualifying financial statements:

- Audit letter, if audited;
- Balance Sheet;
- Statement of Income;
- Statement of Cash Flows;
- Statement of Retained Earnings (Statement of Changes in Stockholders' Equity);
- Financial Notes

Financial Statement Requirements:

- Financial statements must be published together with this disclosure statement as one document.
- Financial statements must be "machine readable." Do not publish images/scans of financial statements.
- Financial statements must be presented with comparative financials against the prior FYE or period, as applicable.
- Financial statements must be prepared in accordance with U.S. GAAP or International Financial Reporting Standards (IFRS) but are not required to be audited.

⁷ The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

10) Issuer Certification

Principal Executive Officer:

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, RYAN GRESHAM certify that:

1. I have reviewed this Disclosure Statement for quarterly disclosure statement of FULL ALLIANCE GROUP, INC. FKA BEVERLY HILLS GROUP, INC. AND THE MOTION PICTURE HALL OF FAME, INC.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 15, 2026 [Date]

/s/ RYAN GRESHAM [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Principal Financial Officer:

I, WILLIAM HENEGHAN III certify that:

1. I have reviewed this Disclosure Statement for quarterly disclosure statement of FULL ALLIANCE GROUP, INC. FKA BEVERLY HILLS GROUP, INC. AND THE MOTION PICTURE HALL OF FAME, INC.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

May 15, 2026 [Date]

/s/ WILLIAM HENEGHAN III [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

Full Alliance Group, Inc.
Consolidated Balance Sheets
(Unaudited)

	March 31, 2026	December 31, 2025
	<hr/>	<hr/>
ASSETS		
Current Assets:		
Cash and Cash Equivalents	186,275	\$ 98,768
Accounts Receivable	269,991	269,536
Inventory	545,015	650,751
Other Receivable	55,492	50,350
Total Current Assets	<hr/> 1,056,774	<hr/> 1,069,405
Other Assets:		
Equipment, net of Depreciation	906,691	918,832
Software, net of Amortization	200,090	200,090
Deposits	26,890	65,492
Goodwill	1,454,975	1,454,975
Investments in Subsidiaries	2,296,507	2,085,104
TOTAL ASSETS	<hr/> \$ 5,941,927	<hr/> \$ 5,793,898
LIABILITIES & STOCKHOLDERS' EQUITY		
Current Liabilities:		
Accounts Payable and Accrued Liabilities	567,734	584,782
Total Current Liabilities	<hr/> 567,734	<hr/> 584,782
Other Liabilities:		
Convertible Note Payable	128,294	128,007
Related Parties Payable	133,221	99,184
Non-Related Party Payable	1,286,696	1,302,036
Non-Related Party Payable - Convertible Notes	256,959	254,205
Total Liabilities	<hr/> 2,372,904	<hr/> 2,368,214
Stockholders' Equity		
Preferred Stock, \$0.001 par value, 150,000,000 shares authorized; 100,401,910 and 98,926,910 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively	100,401	100,401
Common Stock, \$0.001 par value, 850,000,000 shares authorized, 135,788,511 and 123,949,711 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively	248,394	248,394
Additional Paid-In Capital	16,505,517	16,505,517
Non-Controlling Interest APIC	(169,000)	(169,000)
Total Additional Paid-In Capital	<hr/> 16,336,517	<hr/> 16,336,517
Accumulated Deficit Controlling Interest	(13,140,510)	(13,193,849)
Non-Controlling Interest (Deficit)	24,221	(65,778)
Total Accumulated Deficit	<hr/> (13,116,288)	<hr/> (13,259,627)
Total stockholder's equity	<hr/> 3,569,024	<hr/> 3,425,685
Subsidiaries Equity		
TOTAL LIABILITIES AND STOCKHOLDER'S DEFICIT	<hr/> \$ 5,941,927	<hr/> \$ 5,793,898

The accompanying notes are an integral part of these unaudited consolidated financial statements

Full Alliance Group, Inc.
Consolidated Statements of Operations
(Unaudited)

For The Three Months Ended
March 31,

	<u>2026</u>	<u>2025</u>
Revenue	\$ 1,166,660	\$ 708,877
Cost of Goods Sold	<u>498,676</u>	<u>135,398</u>
Gross profit	<u>667,984</u>	<u>573,479</u>
Expenses:		
Selling, General and Administrative Expenses	<u>496,998</u>	<u>631,450</u>
Total operating expenses	<u>496,998</u>	<u>631,450</u>
Operating income (loss)	170,986	(57,971)
Other Income (Expense)		
Interest Expense	<u>(27,647)</u>	<u>(41,874)</u>
Total Other Income (Expense)	<u>(27,647)</u>	<u>(41,874)</u>
Net Income (Loss)	<u>\$ 143,339</u>	<u>\$ (99,845)</u>
Net Income (Loss) Attributable to Parent	\$ 53,339	\$ (71,387)
Net Income (Loss) Non-Controlling Interest	\$ 89,999	\$ (28,457)
Basic and diluted loss per common share	<u>-</u>	<u>\$ -</u>
Weighted average common shares outstanding	<u>135,788,511</u>	<u>123,949,611</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements

Full Alliance Group, Inc.
Consolidated Statements of Stockholders' Equity
For The Three Months Ended March 31, 2026 and The Seven Years Ended December 31, 2025, 2024, 2023, 2022, 2021, 2020, and 2019
(Unaudited)

	Preferred Stock		Common Stock			Additional Paid In Capital Amount	Accumulated Deficit Amount	Total Amount
	Shares	Par Amount	Shares (After Split)	Shares (Before Split)	Par Amount			
Balance, December 31, 2018	25,000,000	\$ 25,000	59,343,301	181,354,625	\$ 181,353	\$ 7,480,294	\$ (8,510,932)	\$ (824,284)
Issuance of Preferred Shares for Investment	25,000,000	25,000	-	-	-	987,500	-	1,012,500
Issuance of Shares for Investment	-	-	5,000,000	5,000,000	5,000	35,500	-	40,500
Issuance of Shares for Debt	-	-	16,200,000	16,200,000	16,200	26,800	-	43,000
Issuance of Shares for Services	-	-	7,000,000	7,000,000	7,000	826,700	-	833,700
Net Loss	-	-	-	-	-	-	(975,174)	(975,174)
Balance, December 31, 2019	50,000,000	\$ 50,000	87,543,301	209,554,625	\$ 209,553	\$ 9,356,794	\$ (9,486,106)	\$ 130,242
Balance, December 31, 2019	50,000,000	\$ 50,000	87,543,301	209,554,625	\$ 209,553	\$ 9,356,794	\$ (9,486,106)	\$ 130,242
Issuance of Shares for Services	-	-	10,000,000	10,000,000	10,000	353,000	-	363,000
Increase of Preferred Shares	-	-	-	-	-	-	-	-
Conversion Only for Investment	-	-	-	-	-	626,512	-	626,512
Net Loss	-	-	-	-	-	-	(413,997)	(413,997)
Balance, December 31, 2020	50,000,000	\$ 50,000	97,543,301	219,554,625	\$ 219,554	\$ 10,336,306	\$ (9,900,103)	\$ 705,757
Balance, December 31, 2020	50,000,000	\$ 50,000	97,543,301	219,554,625	\$ 219,554	\$ 10,336,306	\$ (9,900,103)	\$ 705,757
Issuance of Shares for Debt Conversion	-	-	4,867,410	4,867,410	4,867	7,301	-	12,169
Prior Period Adjustment to Deficit	-	-	-	-	-	-	(3,498)	(3,498)
Net Loss	-	-	-	-	-	-	(21,360)	(21,360)
Balance, December 31, 2021	50,000,000	\$ 50,000	102,410,711	224,422,035	\$ 224,421	\$ 10,343,607	\$ (9,924,961)	\$ 693,068
Balance, December 31, 2021	50,000,000	\$ 50,000	102,410,711	224,422,035	\$ 224,421	\$ 10,343,607	\$ (9,924,961)	\$ 693,068
Prior Period Adjustment to Deficit	-	-	-	-	-	-	6,373	6,373
Net Loss	-	-	-	-	-	-	(29,473)	(29,473)
Balance, December 31, 2022	50,000,000	\$ 50,000	102,410,711	224,422,035	\$ 224,421	\$ 10,343,607	\$ (9,948,061)	\$ 669,967
Balance, December 31, 2022	50,000,000	\$ 50,000	102,410,711	224,422,035	\$ 224,421	\$ 10,343,607	\$ (9,948,061)	\$ 669,967
Effect of Reverse Merger with Bio Lab Naturals, Inc.	59,136,910	59,136	-	-	-	1,875,399	-	1,934,535
Cancel of Preferred Shares for Investment	(25,000,000)	(25,000)	-	-	-	(987,500)	-	(1,012,500)
Issuance of Shares for Debt	-	-	4,000,000	4,000,000	4,000	6,000	-	10,000
Net Loss	-	-	-	-	-	-	(430,584)	(430,584)
Balance, March 31, 2023	84,136,910	\$ 84,136	106,410,711	228,422,035	\$ 228,421	\$ 11,237,506	\$ (10,378,645)	\$ 1,171,418
Balance, March 31, 2023	84,136,910	\$ 84,136	106,410,711	228,422,035	\$ 228,421	\$ 11,237,506	\$ (10,378,645)	\$ 1,171,418
Effect of Purchase of Dynamaxx	11,000,000	11,000	-	-	-	1,463,000	-	1,474,000
Issuance of Shares for Debt	-	-	5,000,000	5,000,000	5,000	7,500	-	12,500
Net Loss	-	-	-	-	-	-	(261,643)	(261,643)
Balance, June 30, 2023	95,136,910	\$ 95,136	111,410,711	233,422,035	\$ 233,421	\$ 12,708,006	\$ (10,640,288)	\$ 2,396,275
Balance, June 30, 2023	95,136,910	\$ 95,136	111,410,711	233,422,035	\$ 233,421	\$ 12,708,006	\$ (10,640,288)	\$ 2,396,275
Series F Preferred Stock Subscribed For	-	-	-	-	-	-	-	-
Net Loss	-	-	-	-	-	-	(59,170)	(59,170)
Balance, September 30, 2023	95,136,910	\$ 95,136	111,410,711	233,422,035	\$ 233,421	\$ 12,708,006	\$ (10,699,458)	\$ 2,337,105
Balance, September 30, 2023	95,136,910	\$ 95,136	111,410,711	233,422,035	\$ 233,421	\$ 12,708,006	\$ (10,699,458)	\$ 2,337,105
Series F Preferred Stock Subscribed For	-	-	-	-	-	550,000	-	550,000
Net Loss	-	-	-	-	-	-	(251,609)	(251,609)
Balance, December 31, 2023	95,136,910	\$ 95,136	111,410,711	233,422,035	\$ 233,421	\$ 13,258,006	\$ (10,951,067)	\$ 2,635,496
Balance, December 31, 2023	95,136,910	\$ 95,136	111,410,711	233,422,035	\$ 233,421	\$ 13,258,006	\$ (10,951,067)	\$ 2,635,496
Series F Preferred Stock Subscribed For	-	-	-	-	-	(550,000)	-	(550,000)
Series F Issued March 29, 2024	2,670,000	2,670	-	-	-	1,332,330	-	1,335,000
Non-Controlling Interest	-	-	-	-	-	(39,157)	-	(39,157)
Net Loss	-	-	-	-	-	-	(510,301)	(510,301)
Non-Controlling Interest Net Loss	-	-	-	-	-	-	4,843	4,843
Balance, March 31, 2024	97,806,910	\$ 97,806	111,410,711	233,422,035	\$ 233,421	\$ 14,001,179	\$ (11,456,525)	\$ 2,875,881
Balance, March 31, 2024	97,806,910	\$ 97,806	111,410,711	233,422,035	\$ 233,421	\$ 14,001,179	\$ (11,456,525)	\$ 2,875,881
Series F Issued During Quarter ending 6/30/2024	370,000	370	-	-	-	369,630	-	370,000
Non-Controlling Interest	-	-	-	-	-	(37,981)	-	(37,981)
Net Loss	-	-	-	-	-	-	(722,178)	(722,178)
Non-Controlling Interest Net Loss	-	-	-	-	-	-	15,204	15,204
Balance, June 30, 2024	98,176,910	\$ 98,176	111,410,711	233,422,035	\$ 233,421	\$ 14,332,828	\$ (12,163,499)	\$ 2,500,926
Balance, June 30, 2024	98,176,910	\$ 98,176	111,410,711	233,422,035	\$ 233,421	\$ 14,332,828	\$ (12,163,499)	\$ 2,500,926
Series F Issued During Quarter ending 9/30/2024	730,000	730	-	-	-	729,270	-	730,000
Non-Controlling Interest	-	-	-	-	-	(48,558)	-	(48,558)
Net Loss	-	-	-	-	-	-	(344,366)	(344,366)
Non-Controlling Interest Net Loss	-	-	-	-	-	-	(15,486)	(15,486)
Balance, Sept 30, 2024	98,906,910	\$ 98,906	111,410,711	233,422,035	\$ 233,421	\$ 15,013,541	\$ (12,523,351)	\$ 2,822,516
Balance, Sept 30, 2024	98,906,910	\$ 98,906	111,410,711	233,422,035	\$ 233,421	\$ 15,013,541	\$ (12,523,351)	\$ 2,822,516
Issuance of Shares for Debt	-	-	12,538,900	-	3,134	28,213	-	31,347
Series F Issued During Quarter ending 12/31/2024	20,000	20	-	-	-	9,980	-	10,000
Members Equity	-	-	-	-	-	575,000	-	575,000
Non-Controlling Interest (adjustment)	-	-	-	-	-	(115,000)	-	(115,000)

Net Loss							(361,967)	(361,967)
Non-Controlling Interest Net Loss							(1,922)	(1,922)
Balance, December 31, 2024	98,926,910	98,926	123,949,611	233,422,035	236,555	15,511,734	(12,887,240)	2,959,975
Balance, December 31, 2024	98,926,910	98,926	123,949,611	233,422,035	236,555	15,511,734	(12,887,240)	2,959,975
Series F Issued During Quarter ending 3/31/2025	60,000	\$ 60				29,940		30,000
Members Equity						125,000		125,000
Non-Controlling Interest (adjustment)						(54,000)		(54,000)
Net Loss							(71,387)	(71,387)
Non-Controlling Interest Net Loss							(28,457)	(28,457)
Balance, March 31, 2025	98,986,910	98,986	123,949,611	233,422,035	236,555	15,612,674	(12,987,084)	2,961,130
Balance, March 31, 2025	98,986,910	98,986	123,949,611	233,422,035	236,555	15,612,674	(12,987,084)	2,961,130
Series F Issued During Quarter ending 6/30/2025	535,000	\$ 535				266,965		267,500
Issuance of Shares for Debt			5,538,900		5,539	8,308		13,847
Members Equity						-		-
Non-Controlling Interest (adjustment)						-		-
Net Loss							(190,502)	(190,502)
Non-Controlling Interest Net Loss							(35,784)	(35,784)
Balance, June 30, 2025	99,521,910	99,521	129,488,511	233,422,035	242,094	15,887,947	(13,213,370)	3,016,191
Balance, June 30, 2025	99,521,910	99,521	129,488,511	233,422,035	242,094	15,887,947	(13,213,370)	3,016,191
Series F Preferred Stock Subscribed For	-	\$ -				440,000		440,000
Members Equity						-		-
Non-Controlling Interest (adjustment)						-		-
Net Loss							(220,739)	(220,739)
Non-Controlling Interest Net Loss							71,120	71,120
Balance, Sept 30, 2025	99,521,910	99,521	129,488,511	233,422,035	242,094	16,327,947	(13,362,989)	3,306,572
Balance, Sept 30, 2025	99,521,910	99,521	129,488,511	233,422,035	242,094	16,327,947	(13,362,989)	3,306,572
Series F Preferred Stock Subscribed For	-	\$ -				(440,000)		(440,000)
Series F Issued During Quarter ending 12/31/2025	880,000	\$ 880				439,120		440,000
Issuance of Shares for Debt			6,300,000		6,300	9,450		15,750
Members Equity						-		-
Non-Controlling Interest (adjustment)						-		-
Net Income (Loss)							138,564	138,564
Non-Controlling Interest Net Loss							(35,201)	(35,201)
Balance, Dec 31, 2025	100,401,910	100,401	135,788,511	233,422,035	248,394	16,336,517	(13,259,627)	3,425,685
Balance, Dec 31, 2025	100,401,910	100,401	135,788,511	233,422,035	248,394	16,336,517	(13,259,627)	3,425,685
Non-Controlling Interest (adjustment)						-		-
Net Income (Loss)							53,339	53,339
Non-Controlling Interest Net Loss							89,999	89,999
Balance, Mar 31, 2026	100,401,910	100,401	135,788,511	233,422,035	248,394	16,336,517	(13,116,288)	3,569,024

The accompanying notes are an integral part of these unaudited consolidated financial statements

Full Alliance Group, Inc.
Consolidated Statements of Cash Flows
(Unaudited)

	For The Three Months Ended	
	March 31,	
	<u>2026</u>	<u>2025</u>
Cash Flow From Operating Activities		
Net Income (Loss)	\$ 143,339	\$ (99,845)
Adjustments to reconcile net loss to net cash used in operating activities:		
Accounts Payable and Accrued Expense	(17,048)	189,296
Depreciation Expense	14,641	14,591
Increase (Decrease) in Inventory	105,736	(42,018)
Accounts Receivable	(455)	8,776
Other Receivable	(5,142)	-
Other Assets	38,602	28
Net Cash Provided in Operating Activities	<u>279,672</u>	<u>70,829</u>
Cash Flow From Investing Activities		
	(213,903)	(210,248)
Net Cash Used in Investing Activities	<u>(213,903)</u>	<u>(210,248)</u>
Cash Flow From Financing Activities		
Series F Preferred Stock	-	25,000
Non-Controlling Interest	-	76,000
Increase (Decrease) in Notes Payable	21,738	94,534
Net Cash From Financing Activities	<u>21,738</u>	<u>195,534</u>
Net Change in Cash	87,507	56,114
Cash at Beginning of Period	<u>\$ 98,768</u>	<u>\$ 12,842</u>
Cash at End of Period	<u>\$ 186,275</u>	<u>\$ 68,956</u>
Net cash paid for:		
Interest	<u>\$ 3,500</u>	<u>\$ 21,551</u>
Income Taxes	<u>-</u>	<u>\$ -</u>

The accompanying notes are an integral part of these unaudited consolidated financial statements

Full Alliance Group, Inc.
(fka Beverly Hills Group, Inc. and Motion Picture Hall of Fame, Inc.)
Notes to Financial Statements
March 31, 2026
(Unaudited)

1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Full Alliance Group, Inc. (fka. Beverly Hills Group, Inc.) (“the Company”) is a Nevada corporation and operates through subsidiaries and joint ventures in nutraceuticals, supplement manufacturing, health-related services, fintech and blockchain product initiatives.

On June 5, 2014, the Company approved an amendment to its articles of incorporation to increase the authorized shares of common stock from 150,000,000 shares to 300,000,000 shares of common stock, each share having a par value of \$0.001 and issue two classes of preferred shares: Preferred Class A and Preferred Class B, each class with 25,000,000 shares with each share bearing a par value of \$0.001, each share bearing voting rights 1 to 10, and each share bearing conversion 1 to 5 into common shares once issued.

On July 8, 2014, the Company effected a 1-for-30 reverse stock split of its issued and outstanding shares of common stock. The par value and number of authorized shares of the common stock remained unchanged. All references in the accompanying financial statements as to the Company’s equity structure and to the number of shares outstanding and per-share amounts have been restated to reflect in the indicated amendment to the articles of incorporation and to the 1:30 reverse stock split.

On October 1, 2014, the Company approved an amendment to its articles of incorporation to increase the authorized common and preferred shares from 300,000,000 shares to 500,000,000 shares. This amendment has not been filed with the Nevada Secretary of State; therefore, it is not affected as of September 30, 2016.

On April 12, 2017, the Company changed its name to Full Alliance Group, Inc., and a symbol change to (OTCPK: FAGI).

On October 17, 2016, the Company effected a 1-for-100 reverse stock split of its issued and outstanding shares of common stock. The par value and number of authorized shares of the common stock remained unchanged. All references in the accompanying financial statements as to the Company’s equity structure and to the number of shares outstanding and per-share amounts have been restated to reflect in the indicated amendment to the articles of incorporation and to the 1:100 reverse stock split.

On February 1, 2019, the Company filed with the Nevada Secretary of State its amendment to its articles of incorporation to increase the authorized common and preferred shares from 300,000,000 common shares to 550,000,000 common shares, including the 50,000,000 preferred shares previously authorized.

On January 22, 2023, the Company entered into an Agreement and Plan of Merger with Bio Lab Naturals, Inc., a Florida corporation, manufacturing supplement products for white/private label customers and for its in-house brand Pure Factors, through its FDA-registered wholly owned subsidiary Pure Solutions, Inc. Pursuant to the Agreement, Full Alliance Group acquired all the outstanding shares of Bio Lab Naturals, Inc., in exchange for Twenty-five million (25,000,000) Class C Preferred Shares and Thirty-four million one hundred and thirty-six thousand nine hundred and ten (34,136,910) Class D Preferred shares, after the exchange, Full Alliance Group owns one hundred (100%) percent of Bio Lab Naturals common stock, and Bio Lab Naturals became a wholly-owned subsidiary of Full Alliance Group.

On February 24, 2023, the Company filed with the Nevada Secretary of State its amendment to its articles of incorporation to increase the authorized common and preferred shares from 500,000,000 common shares to 750,000,000 common shares, and from 50,000,000 preferred shares to 100,000,000 preferred shares.

On April 24, 2023, Full Alliance Group, Inc., trading symbol "FAGI" ("the Company") entered into an Agreement and Plan of Merger with Dynamaxx International, LTD., a Texas company. According to the terms of the Agreement, Full Alliance Group acquired all the outstanding shares of Dynamaxx International, LTD., in exchange for Eleven million (11,000,000) Class E Preferred Shares, a three hundred thousand dollar (\$300,000) promissory note with an accrued interest rate of 5% annually, due and payable three years from the Effective Date of the Agreement and the current Chief Executive Officer of Dynamaxx International, Jay Archer, will enter into an employment agreement for a period of three years starting the later of May 1, 2023 or the Effective Date with a base salary of \$150,000 per annum plus bonus; bonus will be 23% of the increase in EBITDA above \$700,000 generated from the MAXX subsidiary. Full Alliance Group owns one hundred (100%) percent of Dynamaxx International's common stock, and it became a wholly owned subsidiary of Full Alliance Group.

On October 23, 2023, DynaMAXX Health, Inc. was formed as 100% wholly owned subsidiary of Full Alliance Group, Inc., DynaMAXX Health, Inc. formed DynaMAXX Clinics SPV I, LLC on January 3, 2024, and offered its Class B Membership interest to investors under the following terms:

The Class B Membership interest offering is as follows:

Offering: 1,000,000 Class B Membership Interest @ \$1.00 for a total potential offering of \$1,000,000.

Use of Proceeds Open up four-five Maxx Health Clinics in Florida

During the Quarter ending March 31, 2024, DynaMAXX Clinics SPV I, LLC raised \$275,000 and formed its first health clinic MAXX Health Clinic FL I, LLC on March 12, 2024. During the Quarter ending June 30, 2024, DynaMAXX Clinics SPV I, LLC raised an additional \$100,000. During the Quarter ending September 30, 2024, an additional \$150,000 was raised.

On March 29, 2024, four million (4,000,000) Class F Preferred Shares were authorized, par value \$0.001. Series F Preferred are being offered at \$0.50 cents for a total potential offering of \$2,000,000. (Management reserves the right to expand this offering.) Each Class F Preferred Share has antidilution consisting of the following: After a Thirty (30) for One (1) reverse split ("Split") of the common shares each share of Series F Preferred will automatically convert into 10X the amount of common shares. (Example: if the common stock is trading at .01 Cents prior to split, with all things being equal it will be trading at .30 cents after split each \$1 invested in Series F Preferred will receive 20 shares of Common Shares after the Split.) In the first Quarter of 2025, the Board Authorized to expand the offering of Class F Preferred Shares to six million (6,000,000) shares.

On July 5, 2024, the Company entered two joint ventures FV and WL Products International, LLC with the goal to enter the direct-to-consumer ecommerce and Video Sales Letter (“VSL”) space with our own products with FV and to supply white-label products to others through WL, specializing in the supplements and cosmetics industry. The Company owns 51% of each of these entities.

On December 19, 2024, the Company entered a joint venture with hypochlorous acid (“HOCl”) expert Michel Van Schaik to launch a new manufacturing initiative focused on HOCl-based solutions. The venture, named PureAquaox, LLC—of which the Company holds a 51% ownership stake—aims to produce eco-friendly, non-toxic, and highly effective HOCl products for cleaning, sanitizing, and skincare applications. As consumer demand accelerates for natural and chemical-free alternatives, HOCl is emerging as a preferred solution due to its powerful antimicrobial properties, human-safe profile, and broad utility across medical, commercial, and personal care industries. Both parties contributed \$50,000 in initial capital to establish the venture.

On December 18, 2025, the Company filed with the Nevada Secretary of State its amendment to its articles of incorporation to increase the authorized common and preferred shares from 750,000,000 common shares to 850,000,000 common shares, and from 100,000,000 preferred shares to 150,000,000 preferred shares.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated in consolidation.

Revenue Recognition

The Company derives revenues from sales to wholesale customers, private label customers, its own finished goods through sales from physical locations and online channels, shipping and formulation services. It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 “Revenues from Contracts with Customers.” Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation.

The Company recognizes revenue when persuasive evidence of an arrangement exists, transfer of title has occurred or services have been rendered. The selling price is fixed or determinable, no other significant obligations of the Company exist, and the collectability is reasonably assured. The Company’s sales arrangements are not subject to warranty.

Cash and cash equivalents

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company had \$186,275 of cash and cash equivalents as of March 31, 2026.

Accounts Receivable

Accounts receivables are recorded as the invoiced amount and generally do not bear interest. An allowance for doubtful accounts is established, as necessary, based on experience and other factors which, in the management's judgment, deserve current recognition in estimating bad debts. Such factors include growth and composition of accounts receivable, the relationship of the allowance for doubtful accounts to accounts receivable, and current economic conditions. The determination of the collectability of amounts due requires the Company to make judgments regarding future events and trends. Allowances for doubtful accounts are determined based on assessing the Company's portfolio on an individual customer and on an overall basis. This process consists of a review of historical collection experience, current aging status of the customer account, and the financial condition of the Company's customers. Based on a review of these factors, the Company establishes or adjusts the allowance for specific customers and the accounts receivable portfolio as a whole. At March 31, 2026, an allowance for doubtful accounts was established for a customer from 2023 and was established in the amount of \$179,939 as it was not deemed collectible.

Inventories

Inventories are valued at the lower of cost or market. Cost is determined using the first-in, first-out method for all inventories, which are valued using a weighted average cost method calculated for each production batch.

Property and Equipment

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred. Additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and a gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives of five to seven years.

Investment

In February 2019, The Company entered into a Stock for Stock Acquisition Agreement, pursuant to which two companies have become wholly owned subsidiaries of the Company. The Company issued out 25,000,000 series "B" Preferred stock and 5,000,000 Restricted Common Shares to the subsidiaries' original sole shareholder. As part of the January 22, 2023, Agreement and Plan of Merger with Bio Lab Naturals, Inc. the Company cancelled 25,000,000 series "B" Preferred stock issued on February 2019 and issued out 25,000,000 series "C" Preferred stock and 34,136,910 series "D" Preferred stock to the Bio Lab Naturals' original shareholders.

In April 2023, the Company entered into a Stock Purchase Agreement with DynaMAXX, pursuant to which DynaMAXX has become a wholly owned subsidiary of the Company. The Company issued out 11,000,000 series "E" Preferred stock to the newly acquired subsidiary's sole partner.

At various times during the Quarter ending March 31, 2024, DynaMAXX Clinics SPV I, LLC raised \$275,000 from two investors pursuant to its Class B Membership interest offering.

On March 29, 2024, four million (4,000,000) Class F Preferred Shares were authorized, par value \$0.001. Series F Preferred are being offered at \$0.50 cents for a total potential offering of \$2,000,000. (Management reserves the right to expand this offering.) Each Class F Preferred Share has antidilution consisting of the following: After a Thirty (30) for One (1) reverse split (“Split”) of the common shares each share of Series F Preferred will automatically convert into 10X the amount of common shares. (Example: if the common stock is trading at .01 Cents prior to split, with all things being equal it will be trading at .30 cents after split each \$1 invested in Series F Preferred will receive 20 shares of Common Shares after the Spilt.) In the first Quarter of 2025, the Board Authorized to expand the offering of Class F Preferred Shares to six million (6,000,000) shares.

On April 9, 2024, DynaMAXX Clinics SPV I, LLC raised \$100,000 from one investor pursuant to its Class B Membership interest offering.

During the Quarter ended June 30, 2024, the Company raised an additional \$185,000 from the sale of its Class F Preferred Shares.

During the Quarter ended September 30, 2024, the Company raised an additional \$355,000 from the sale of its Class F Preferred Shares bringing the total raised to \$1,875,000.

During the Quarter ended September 30, 2024, DynaMAXX Clinics SPV I, LLC raised \$150,000 from two investors pursuant to its Class B Membership interest offering.

During the Quarter ended December 31, 2024, DynaMAXX Clinics SPV I, LLC raised \$50,000 from one investor pursuant to its Class B Membership interest offering.

During the Quarter ended June 30, 2025, the Company raised \$100,000 from the sale of its Class F Preferred Stock, Issued \$100,000 as consideration for entering the Joint Venture Agreement with FV Products International LLC, Issued \$25,000 as consideration for entering the Joint Venture Agreement with Aquaox Pure Solutions LLC, and issued \$32,500 as consideration for entering into two loan agreements, the Company recorded \$32,500 as interest expense.

As of September 30, 2025, the Company had already issued \$2,192,500 and an additional \$440,000 subscribed of its Class F Preferred from twenty-five shareholders.

During the Quarter ended December 31, 2025, the Company issued 880,000 Class F Preferred Shares for the \$440,000 subscribed for in the previous quarter.

Use of Estimates

The Preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Income Taxes

The Company accounts for its income taxes under the provisions of ASC Topic 740, “Income Taxes.” The method of accounting for income taxes under ASC 740 is an asset and liability method. The asset and liability method

requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between tax bases and financial reporting bases of other assets and liabilities. The Company had no material unrecognized income tax assets or liabilities for the three months ended March 31, 2026. The Company recognizes income tax interest and penalties as a separately identified component of general and administrative expense. During the three months ended March 31, 2026, there were no income tax, or related interest and penalty items in the income statement, or liabilities on the balance sheet.

Issuance of Shares for Service

The Company accounts for the issuance of equity instruments to acquire goods and services based on the fair value of the goods and services or the fair value of the equity instrument at the time of issuance, whichever is more reliably measurable. During the Quarter ended September 30, 2024, the Company issued \$10,000 of Series F Preferred stock to a consultant.

Stock-based Compensation

The Company accounts for stock-based compensation under ASC Topic 505-50, formerly Statement of Financial Accounting Standards (“SFAS”) No. 123R, “Share-Based Payment” and SFAS No. 148, “Accounting for Stock-Based Compensation – Transition and Disclosure – An amendment to SFAS No. 123.” These standards define a fair-value-based method of accounting for stock-based compensation.

Basic and diluted net loss per Share

The Company reports earnings (loss) per share in accordance with ASC Topic 260-10, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company did not have any dilutive instruments outstanding as of March 31, 2026.

Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred net losses of \$13,116,288 from inception to March 31, 2026, and as of March 31, 2026, has working capital of \$489,040. In addition, the Company’s cash flow requirements have been met by the generation of capital through private placements of the Company’s common stock and loans. No assurance can be given that this source of financing will continue to be available to the Company and demand for the Company’s equity instruments will be sufficient to meet its capital needs. The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis, to retain its current financing, to obtain additional financing, and ultimately to generate revenues.

3. INTANGIBLE ASSETS

As the intangible assets have no defined life, the intangible assets acquired are not subject to amortization. In accordance with ASC 350, "Goodwill and Other Intangible Assets", An intangible asset that is not subject to amortization shall be tested for impairment annually and more frequently if events or changes in circumstances indicate that it is more likely than not that the asset is impaired. As of March 31, 2026, the Company has no intangible assets recorded other than Goodwill.

4. LOAN PAYABLE AND CONVERTIBLE NOTE PAYABLE

In August 2002, the Company received a loan from an unrelated individual ("original holder") amounting to \$180,000. Interest on this loan is \$1,050 per month and payable monthly. The loan was due and payable on October 30, 2007. On May 29, 2014, after the debt was assigned to another party ("new holder"), the Company issued a replacement convertible promissory note to the new holder of this debt in the principal amount of \$335,850 with a due date on August 12, 2017. The new holder is a related party and is controlled by a shareholder of the Company.

The face amount of the new note reflects the principal and accrued interest of the August 2002 loan payable through March 31, 2014, which was originally due to the old holder and subsequently transferred to the new holder. The convertible promissory note accrues interest at 6% per annum and permits the holder to convert principal, excluding accrued interest, subject to a 9.99% ownership limitation, into shares or common stock at a conversion price of \$0.0025 per share.

On August 1, 2014, the new holder assigned and transferred the note to another unrelated entity ("unrelated holder").

On November 15, 2014, the Company received a conversion notice requesting the issuance of 5,081,734 shares upon conversion of \$12,704.34 of the note's outstanding balance, leaving a principal amount of \$323,145.66. The Company issued out 5,081,734 shares on January 6, 2015.

On April 6 2015, the Company received a conversion notice requesting the issuance of 5,790,000 shares upon conversion of \$14,475.00 of the note's outstanding balance, leaving a principal amount of \$308,670.66. The Company issued out 5,790,000 shares on April 6, 2015.

On June 19, 2015, the Company received a conversion notice requesting the issuance of 6,315,200 shares upon conversion of \$15,788.00 of the note's outstanding balance, leaving a principal amount of \$292,882.66. The Company issued 6,315,200 shares on June 19, 2015.

On July 17, 2015, the Company received a conversion notice requesting the issuance of 7,000,000 shares upon conversion of \$17,500.00 of the note's outstanding balance, leaving a principal amount of \$275,382.66. The Company issued out 7,000,000 shares on July 21, 2015.

On April 1, 2016, the Company received a conversion notice requesting the issuance of 5,588,800 shares upon conversion of \$13,972.00 of the note's outstanding balance, leaving a principal amount of \$261,410.66. The Company issued out 5,588,800 shares on April 6, 2016.

On August 23, 2016, the Company received a conversion notice requesting the issuance of 5,000,000 shares upon conversion of \$12,500.00 of the note's outstanding balance, leaving a principal amount of \$248,910.66. The Company issued out 5,000,000 shares on September 6, 2016.

On November 30, 2016, the Company received a conversion notice requesting the issuance of 720,000 shares upon conversion of \$1,800.00 of the note's outstanding balance, leaving a principal amount of \$247,110.66. The Company issued out 720,000 shares on November 30, 2016.

On December 19, 2016, the Company received a conversion notice requesting the issuance of 1,500,000 shares upon conversion of \$3,750.00 of the note's outstanding balance, leaving a principal amount of \$243,360.66. The Company issued out 1,500,000 shares on December 19, 2016.

On January 4, 2017, the Company received a conversion notice requesting the issuance of 1,700,000 shares upon conversion of \$4,250.00 of the note's outstanding balance, leaving a principal amount of \$239,110.66. The Company issued out 1,700,000 shares on January 4, 2017.

On April 17, 2017, the Company received a conversion notice requesting the issuance of 955,715 shares upon conversion of \$2,389.29 of the note's outstanding balance, leaving a principal amount of \$236,721.37. The Company issued out 955,715 shares on April 17, 2017.

On June 1, 2017, the Company received a conversion notice requesting the issuance of 500,000 shares upon conversion of \$2,500 of the note's outstanding balance, leaving a principal amount of \$234,221.37. The Company issued out 500,000 shares on June 1, 2017.

On August 3, 2017, the Company received a conversion notice requesting the issuance of 1,178,000 shares upon conversion of \$2,945 of the note's outstanding balance, leaving a principal amount of \$231,276.37. The Company issued out 1,178,000 shares on August 3, 2017.

On November 30, 2017, the Company received a conversion notice requesting the issuance of 1,200,000 shares upon conversion of \$3,000 of the note's outstanding balance, leaving a principal amount of \$228,276.37. The Company issued out 1,200,000 shares on November 30, 2017.

On December 4, 2017, the Company received a conversion notice requesting the issuance of 1,000,000 shares upon conversion of \$2,500 of the note's outstanding balance, leaving a principal amount of \$225,776.37. The Company issued out 1,000,000 shares on December 4, 2017.

On December 18, 2017, the Company received a conversion notice requesting the issuance of 1,200,000 shares upon conversion of \$3,000 of the note's outstanding balance, leaving a principal amount of \$222,776.37. The Company issued out 1,200,000 shares on December 18, 2017.

On January 19, 2018, the Company received a conversion notice requesting the issuance of 1,700,000 shares upon conversion of \$4,250 of the note's outstanding balance, leaving a principal amount of \$218,526.37. The Company issued out 1,700,000 shares on January 19, 2018.

On March 08, 2018, the Company received a conversion notice requesting the issuance of 1,800,000 shares upon conversion of \$4,500 of the note's outstanding balance, leaving a principal amount of \$214,026.37. The Company issued out 1,800,000 shares on March 08, 2018.

On March 26, 2018, the Company received a conversion notice requesting the issuance of 1,800,000 shares upon conversion of \$4,500 of the note's outstanding balance, leaving a principal amount of \$209,526.37. The Company issued out 1,800,000 shares on March 26, 2018.

On April 11, 2018, the Company received a conversion notice requesting the issuance of 2,100,000 shares upon conversion of \$5,250 of the note's outstanding balance, leaving a principal amount of \$204,276.37. The Company issued out 2,100,000 shares on April 11, 2018.

On May 10, 2018, the Company received a conversion notice requesting the issuance of 1,800,000 shares upon conversion of \$4,500 of the note's outstanding balance, leaving a principal amount of \$199,776.37. The Company issued out 1,800,000 shares on May 10, 2018.

On July 13, 2018, the Company received a conversion notice requesting the issuance of 2,200,000 shares upon conversion of \$5,500 of the note's outstanding balance, leaving a principal amount of \$194,276.37. The Company issued out 2,200,000 shares on July 13, 2018.

On September 14, 2018, the Company received a conversion notice requesting the issuance of 3,500,000 shares upon conversion of \$8,750 of the note's outstanding balance, leaving a principal amount of \$185,526.37. The Company issued out 3,500,000 shares on September 14, 2018.

On February 22, 2019, the Company received a conversion notice requesting the issuance of 4,100,000 shares upon conversion of \$10,250 of the note's outstanding balance, leaving a principal amount of \$175,276.37. The Company issued out 4,100,000 shares on February 22, 2019.

On July 16, 2019, the Company received a conversion notice requesting the issuance of 5,000,000 shares upon conversion of \$15,000 of the note's outstanding balance, leaving a principal amount of \$160,276.37. The Company issued out 5,000,000 shares on July 16, 2019.

On November 22, 2019, the Company received a conversion notice requesting the issuance of 7,100,000 shares upon conversion of \$17,750 of the note's outstanding balance, leaving a principal amount of \$142,526.37. The Company issued out 7,100,000 shares on November 22, 2019.

On January 15, 2016, the Company signed a convertible promissory note of \$45,000 with an unrelated individual. The repayment date is within one year, with accrual interest at 12% per annum.

On August 16, 2017, the Company received a conversion notice requesting the issuance of 500,000 shares upon conversion of \$10,150 of the note's outstanding balance, leaving a principal amount of \$34,850. The Company issued out 500,000 shares on August 22, 2017.

On October 2, 2018, the Company received a conversion notice requesting the issuance of 5,756,971 shares upon conversion of \$59,872.50 of the note's outstanding balance, leaving a principal amount of \$0.00. The Company issued out 5,756,971 shares on October 2, 2018.

On November 7, 2024, the Company received a conversion notice requesting the issuance of 7,000,000 shares upon conversion of \$17,500.00 of the note's outstanding balance, leaving a principal amount of \$49,026.37. The Company issued out 7,000,000 shares on December 18, 2024.

On November 15, 2024, the Company received a conversion notice requesting the issuance of 5,538,900 shares upon conversion of \$13,847.25 of the note's outstanding balance, leaving a principal amount of \$35,179.12. The Company issued out 5,538,900 shares on December 18, 2024.

On July 1, 2025, Global Force Trading Limited assigned their Note, in the amount of \$35,179.12 principal and \$107,655.74 accrued interest to New Orleans Private Wealth Management, LLC.

On November 7, 2025, the Company received a conversion notice from New Orleans Private Wealth Management, LLC requesting the issuance of 6,300,000 shares upon conversion of \$15,750 of the note's outstanding balance leaving a balance of \$128,007 with a principal amount of \$19,429 and accrued interest of \$108,578 on December 31, 2025. During the Quarter ending December 31, 2025, the Company issued such shares.

As part of the January 22, 2023, Agreement and Plan of Merger with Bio Lab Naturals, Inc. the Company assumed the following unrelated party notes (Balances as of March 31, 2026):

	Origination Date	Principal Balance at 3/31/26	Annual Interest Rate	Accrued Interest at 3/31/26	Total Due 3/31/26
At 3/31/26					
Admiral Advisors LLC	5/10/22	\$ 306,075.10	13.00%	\$ 9,811.17	\$ 315,886.28
Tetrad Consulting LLC	8/31/22	\$ 15,000.00	12.00%	\$ 6,000.00	\$ 21,000.00
Merchbot LLC	8/31/22	\$ 20,000.00	12.00%	\$ 8,000.00	\$ 28,000.00
SBA Loan	11/4/21	\$ 493,925.57	3.75%	\$ 77,580.71	\$ 571,506.28

As part of the April 24, 2023, Acquisition of DynaMAXX International LTD., the Company issued the following Note to Jay Archer a related party due to such Acquisition.

	Origination Date	Principal Balance at 3/31/26	Annual Interest Rate	Accrued Interest at 3/31/26	Total Due 3/31/26
At 3/31/26					
Jay Archer	5/24/23	\$ 300,000.00	5.00%	\$ 40,250.00	\$ 340,250.00

On July 18, 2024, the Company received a loan from Admiral Advisors, LLC in the amount of \$60,000 which accrues interest of 13% annually. On September 10, 2024, the Company paid back \$30,000 plus accrued interest. The remaining \$30,000 was added to the original Admiral Advisors loan. At September 30, 2025, the Company has a total principal balance of \$255,709.14 and accrued interest of \$7,463.72 as shown above. During the quarter ended December 31, 2024, on October 29, 2024, and on two Dates in December 2024, Admiral advanced an additional

\$65,000 and 16,920, respectively. During Q1 2025, Admiral advanced an additional \$45,500 at various dates which is reflected in balance above. During Q2 2025, Admiral advanced an additional \$15,000 at various dates which is reflected in the balance above.

During the quarter ended March 31, 2025, an individual loaned the Company \$100,000 with a term of one year. Interest is due monthly at 18% per annum and principal is due on maturity in January 2026. For the quarter ending December 31, 2025, the Company paid interest of \$4,500 pursuant to this note and the note had an outstanding balance of \$98,500 at year end. Subsequent to year end the Company has made a principal payment of \$40,000.

UNRELATED PARTY NOTE ASSIGNED TO UNRELATED PARTY:

On March 25, 2021, the unrelated party Note Holder assigned and transferred a \$76,000.00 portion of the Convertible Note, having an outstanding balance of principle plus interest of \$157,315.93 as of March 25, 2021, to another unrelated entity ("unrelated Holder"), and permits the unrelated Holder to convert principal, into shares of common stock at a conversion price of \$0.0025 per share.

On May 25, 2021, the Company received a conversion notice requesting the issuance of 4,867,410 shares upon conversion of \$12,168.53 of the note's outstanding balance, leaving a principal amount of \$63,831.47. The Company issued out 4,867,410 shares on June 11, 2021.

On January 22, 2023, the unrelated party Note Holder, reduced and cancel 50% of the outstanding balance of its Convertible Note, thereby reducing the outstanding balance to \$38,683.52.

On March 8, 2023, the Company received a conversion notice requesting the issuance of 4,000,000 shares upon conversion of \$10,000.00 of the note's outstanding balance, leaving a principal & interest amount of \$28,683.52. The Company issued out 4,000,000 shares on March 23, 2023.

On April 17, 2023, the Company received a conversion notice requesting the issuance of 5,000,000 shares upon conversion of \$12,500.00 of the note's outstanding balance, leaving a principal & interest amount of \$16,183.52. The Company issued out 5,000,000 shares on April 17, 2023.

On June 7, 2023, FAGI and Pinnacle Consulting Services, Inc. entered into a Settlement Agreement which extinguished all outstanding balance of its Convertible Note of \$16,332.49.

5. RELATED PARTY PAYABLE

As of December 31, 2023, 2022, the Company had related party payables in the amount of \$45,000.

A related third party made advances and directly paid Company expenses. The related party is controlled by the major shareholder of the Company. The Company issued convertible promissory notes which accrues interest at 6% per annum and permits the holder to convert principal, excluding any accrued interests, into shares of common stock at a conversion price of \$0.0025 per share.

On March 10, 2016, the Company received a conversion notice requesting the issuance of 35,000,000 shares upon conversion of \$87,500.00 of the note's outstanding balance, leaving a principal amount of \$744,611.52. The Company issued out 35,000,000 shares on March 10, 2016.

On November 25, 2016, the Company received a conversion notice requesting the issuance of 6,800,000 shares upon conversion of \$17,000.00 of the note's outstanding balance, leaving a principal amount of \$957,880.21. The Company issued out 6,800,000 shares on November 25, 2016.

On December 8, 2016, the Company received a conversion notice requesting the issuance of 7,200,000 shares upon conversion of \$18,000.00 of the note's outstanding balance, leaving a principal amount of \$939,880.21. The Company issued out 7,200,000 shares on December 8, 2016.

On September 30, 2017, the Company renegotiated with the debt holder to convert \$1,000,000 of the note's outstanding balance in exchange for 25,000,000 preferred shares, leaving a principal amount of \$241,239.60. The Company approved and issued out 25,000,000 preferred stock on September 30, 2017.

On November 28, 2017, the Company received a conversion notice requesting the issuance of 10,000,000 shares upon conversion of \$25,000.00 of the note's outstanding balance, leaving a principal amount of \$256,620.29. The Company issued out 10,000,000 shares on November 28, 2017.

RELATED PARTY NOTE ASSIGNED TO RELATED PARTY:

On July 1, 2019, the note holder assigned and transferred a \$25,000.00 portion of the note to another related entity ("related holder"), and permits the related holder to convert principal, into shares of common stock at a conversion price of \$0.0025 per share.

On July 1, 2019, the note holder assigned and transferred another \$25,000.00 portion of the note to a different related entity ("related holder"), and permits the related holder to convert principal, into shares of common stock at a conversion price of \$0.0025 per share.

On July 8, 2024, 500,000 Restricted Preferred Shares were transferred from Palm Desert Management Inc. to Paul Brian Volpp. in exchange for Paul Brian Volpp to extinguish his outstanding balance of \$25,000.00 Convertible note resulting in a balance of \$0 at September 30, 2024.

On July 8, 2024, 1,000,000 Restricted Preferred Shares were transferred from Palm Desert Management Inc. to Ryan Gresham in exchange for Ryan Gresham to extinguish his outstanding balance of \$28,500.00 Convertible note resulting in a balance of \$0 at September 30, 2024.

These extinguished notes resulted in \$53,500 extraordinary gain for the Company.

RELATED PARTY NOTE ASSIGNED TO UNRELATED PARTY:

On August 20, 2019, the related party note holder assigned and transferred a \$25,000.00 portion of the note to another unrelated entity ("unrelated holder"), and permits the unrelated holder to convert principal, into shares of common stock at a conversion price of \$0.003 per share.

On March 31, 2020, the related party note holder assigned and transferred a \$200,000.00 portion of the note to another unrelated entity ("unrelated holder"), and permits the unrelated holder to convert principal, into shares of common stock at a conversion price of \$0.0025 per share.

On January 23, 2023, the unrelated party note holder assigned and transferred a \$200,000.00 portion of the note to another unrelated entity ("unrelated holder"), and permits the unrelated holder to convert principal, into shares of common stock at a conversion price of \$0.0025 per share.

On November 27, 2023, the unrelated party note holder assigned and transferred a \$200,000.00 portion of the note to another unrelated entity ("unrelated holder"), and permits the unrelated holder to convert principal, into shares of common stock at a conversion price of \$0.0025 per share.

On October 8, 2024, the Company received a conversion notice requesting the issuance of 5,538,900 shares upon conversion of \$13,847.25 of the note's outstanding balance, leaving a principal amount of \$186,152.75. The Company issued out 5,538,900 shares on April 24, 2025.

On March 31, 2020, the Company negotiated a deal with a related party Note holder, who was holding Notes totaling \$437,585.55 principle and \$188,926.51 interest, to convert the total principal and interest into the existing Preferred A shares already held by the related party note holder, by not increasing the amount of Preferred A shares issued, but by increasing only it's convertibility from Preferred A shares to Common Shares, with an increase from 1 to 5 shares to 1 to 7 shares.

On July 8, 2024, 300,000 Restricted Preferred Shares were transferred from Palm Desert Management Inc. to Sung Ho Lee in exchange for Sung Ho Lee to extinguish his outstanding balance of \$25,000.00 Convertible note resulting in a balance of \$0 at September 30, 2024.

This extinguished note resulted in \$25,000 extraordinary gain for the Company.

6. WARRANTS

As of March 31, 2026, the Company has no warrants outstanding.

7. INCOME TAXES

No provision has been made for income taxes. Through March 31, 2026, the Company incurred net operating losses for income tax purposes of approximately \$13,116,288. The net operating loss carryforwards maybe used to reduce taxable income through the year 2039, subject to limitations pursuant IRC Section 382. The net deferred tax asset balance due to net operating loss carryforward as of March 31, 2026, was approximately \$2,754,421. A 100% valuation allowance has been established against the deferred tax asset, as the utilization of the loss carryforward cannot reasonably be assured.

8. SHAREHOLDERS' EQUITY

Effective October 17, 2003, the Company executed a 10 to 1 reverse stock split for all outstanding common stock with par value of \$0.0001.

Effective July 1, 2013 the Company increased its authorized capital to 150,000,000 common shares with \$0.0001 par value.

Effective June 5, 2014 the Company increased its authorized capital to 300,000,000 common shares with \$0.001 par value.

Effective July 8, 2014 the Company split its issued common shares 1 for 30 leaving the authorized capital unchanged.

Effective October 17, 2016 the Company split its issued common shares 1 for 100 leaving the authorized capital unchanged.

All common stock amounts have been retroactively restated to reflect this split as well as the weighted average and per share amounts.

Effective February 24, 2023 the Company increased its authorized capital to 750,000,000 common shares with \$0.001 par value and 100,000,000 preferred shares with \$0.001 par value.

Prior to the end of the Quarter ended September 30, 2023 a shareholder subscribed for Fifty Thousand Dollars of a to be issued Series F Preferred Stock.

Prior to the end of the Quarter ended December 31, 2023, shareholders subscribed for an additional Five Hundred and Fifty Thousand Dollars of a to be issued Series F Preferred Stock bringing the total to Six Hundred Thousand Dollars.

Prior to the end of the Quarter ended March 31, 2024, eleven shareholders invested \$1,335,000 in Series F Preferred stock.

Prior to the end of the Quarter ended June 30, 2024, the Company raised an additional \$185,000 in Series F Preferred stock.

Prior to the end of the Quarter ended September 30, 2024, the Company raised an additional \$355,000 in Series F Preferred stock and issued \$10,000 in Series F Preferred stock to a consultant.

During the Quarter ended March 31, 2025, the Company raised an additional \$30,000 in Series F Preferred stock.

During the Quarter ended March 31, 2025, the Company issued an additional \$267,500 in Series F Preferred stock.

During the Quarter ended September 30, 2025, the Five shareholders subscribed for \$440,000 of the Company's Series F Preferred stock.

During the Quarter ended December 31, 2025, the Company issued 880,000 Series F preferred stock for the \$440,000 previously subscribed for.

Effective December 18, 2025, the Company increased its authorized capital to 850,000,000 common shares with \$0.001 par value and 150,000,000 preferred shares with \$0.001 par value.

9. SUBSEQUENT EVENTS

Subsequent to the quarter ending March 31, 2026, Management has evaluated subsequent events pursuant to the requirements of ASC Topic 855 and has determined that the only material subsequent events are the following:

As mentioned previously, the Company experienced an unforeseen and tragic event involving the death of the medical director of its MAXX Health Clinics operations. As a result of this event, the Company had undertaken a comprehensive review of the future of its clinic operations.

Subsequent to the Quarter ending March 31, 2026, Management entered into a joint venture with an existing health clinic focused on anti-aging and rejuvenation in St. Petersburg, Florida. The Company is in the process of setting up a new entity and has moved some of its medical equipment to the location.